These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 21149673)
1. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. Berg SL; Cairo MS; Russell H; Ayello J; Ingle AM; Lau H; Chen N; Adamson PC; Blaney SM J Clin Oncol; 2011 Jan; 29(3):316-23. PubMed ID: 21149673 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652 [TBL] [Abstract][Full Text] [Related]
3. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292 [TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113 [TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Richardson PG; Schlossman RL; Weller E; Hideshima T; Mitsiades C; Davies F; LeBlanc R; Catley LP; Doss D; Kelly K; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo JJ; Chauhan D; Balinski K; Zeldis J; Anderson KC Blood; 2002 Nov; 100(9):3063-7. PubMed ID: 12384400 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149 [TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813 [TBL] [Abstract][Full Text] [Related]
9. Properties of thalidomide and its analogues: implications for anticancer therapy. Teo SK AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Fangusaro J; Mitchell DA; Kocak M; Robinson GW; Baxter PA; Hwang EI; Huang J; Onar-Thomas A; Dunkel IJ; Fouladi M; Warren KE Pediatr Blood Cancer; 2021 Feb; 68(2):e28756. PubMed ID: 33025730 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Shah SR; Tran TM Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955 [TBL] [Abstract][Full Text] [Related]
12. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092 [TBL] [Abstract][Full Text] [Related]
13. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423 [TBL] [Abstract][Full Text] [Related]
14. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084 [TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181 [TBL] [Abstract][Full Text] [Related]
17. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544 [TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843 [TBL] [Abstract][Full Text] [Related]
19. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440 [TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]